Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Alk Abello AS (OTC: AKBLF).

Full DD Report for AKBLF

You must become a subscriber to view this report.

Recent News from (OTC: AKBLF)

Alk Abello AS (AKBLF) - Investor Presentation - Slideshow
The following slide deck was published by Alk Abello AS in conjunction with this Read more ...
Source: SeekingAlpha
Date: December, 05 2017 10:18
Alk Abello AS ADR 2017 Q3 - Results - Earnings Call Slides
The following slide deck was published by Alk Abello AS ADR in conjunction with their 2017 Q3 earnings Read more ...
Source: SeekingAlpha
Date: November, 13 2017 05:19
ALK-ABELLO AS B SHS 2017 Q2 - Results - Earnings Call Slides
The following slide deck was published by ALK-ABELLO AS B SHS in conjunction with their 2017 Q2 earnings Read more ...
Source: SeekingAlpha
Date: August, 16 2017 13:43
FDA's Flashing Green Light Boosts Novel Drug Approvals
This week's approvals for Puma (PBYI) and Gilead (GILD) mean that the US FDA has given the green light to more novel drugs this year than across the whole of 2016. Fears of a regulatory slowdown, which arose in the wake of last year's drop-off, can be firmly put to bed. The apparent dip now ...
Source: SeekingAlpha
Date: July, 19 2017 14:09
ALK-Abello reports positive child asthma results from Grazax trial
ALK-Abello ( OTC:AKBLF ) releases positive results from a five-year Grazax astham clinical trial. More news on: ALK-ABELLO AS B SHS, Merck & Co Inc., Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: July, 07 2017 08:03
ALK - Five-year GRAZAX(R) Asthma Prevention (GAP) Trial Reveals Benefits of Early Treatment Intervention in Children
HORSHOLM, Denmark , July 7, 2017 The disease modifying property of GRAZAX ® (SQ ® grass SLIT-tablet) resulted in long-term effect on allergic rhinoconjunctivitis (ARC) and prevented asthma symptoms, even two years after end of treatment in children with gr...
Source: PR Newswire
Date: July, 07 2017 05:34
ALK's ACARIZAX(R) Data Results in Significant Change to the GINA Asthma Management Strategy
HORSHOLM, Denmark , Feb. 28, 2017 /PRNewswire/ -- ALK (ALKB: DC / OMX: ALK B / AKABY / AKBLF) today announced that for the first time, allergy immunotherapy is now recommended as a treatment option in the Global Initiative for Asthma (GINA) report: Global Strategy for Asthma Management a...
Source: PR Newswire
Date: February, 27 2017 17:07
Books will close today today March 11th, 2016.
Books will close today today March 11th, 2016.
Source: OTC Markets
Date: March, 11 2016 00:00


About Alk Abello AS (OTC: AKBLF)

Logo for Alk Abello AS (OTC: AKBLF)

Not available


Contact Information



Current Management

  • Per Plotnikof / IR

Current Share Structure

  • Market Cap: $1,289,064,000 - 05/11/2018
  • Issue and Outstanding: 9,207,600 - 12/22/2011


Daily Technical Chart for (OTC: AKBLF)

Daily Technical Chart for (OTC: AKBLF)

Stay tuned for daily updates and more on (OTC: AKBLF)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: AKBLF)

Do your DD and if you choose, be ready to go!


The Research: All source information contained in this email is from the public sources mentioned below.



Thank you

OTC Report



Disclaimer: OTC Report publishes reports providing information on selected companies. OTC Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. OTC Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in AKBLF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. OTC Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. OTC Report does not own any shares of AKBLF and does not buy, sell, or trade any shares of AKBLF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by OTC Report. All rights reserved. Our Full Disclaimer: